171 related articles for article (PubMed ID: 38092470)
1. Hodgkin lymphoma: Focus on evolving treatment paradigms.
Roswarski JL; Longo DL
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470
[TBL] [Abstract][Full Text] [Related]
2. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
3. [Classic Hodgkin lymphoma].
Makita S
Rinsho Ketsueki; 2023; 64(6):504-513. PubMed ID: 37407475
[TBL] [Abstract][Full Text] [Related]
4. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
5. SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma.
Chohan KL; Ansell SM
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):705-713. PubMed ID: 37344332
[TBL] [Abstract][Full Text] [Related]
6. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
7. [Current Standards in the Treatment of Hodgkin Lymphoma].
Hellmuth JC
Dtsch Med Wochenschr; 2024 Jun; 149(12):702-708. PubMed ID: 38781993
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
Choi Y; Diefenbach CS
Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
[No Abstract] [Full Text] [Related]
9. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
10. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.
Hochberg J; Basso J; Shi Q; Klejmont L; Flower A; Bortfeld K; Harrison L; van de Ven C; Moorthy C; Islam H; Gerard P; Voss S; Cairo MS
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584865
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
Pece R; Tavella S; Costa D; Varesano S; Camodeca C; Cuffaro D; Nuti E; Rossello A; Alfano M; D'Arrigo C; Galante D; Ravetti JL; Gobbi M; Tosetti F; Poggi A; Zocchi MR
Haematologica; 2022 Apr; 107(4):909-920. PubMed ID: 34109776
[TBL] [Abstract][Full Text] [Related]
13. Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.
Allen PB; Winter JN
Curr Oncol Rep; 2019 Mar; 21(5):39. PubMed ID: 30919161
[TBL] [Abstract][Full Text] [Related]
14. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
15. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.
Ju W; Zhang M; Wilson KM; Petrus MN; Bamford RN; Zhang X; Guha R; Ferrer M; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1624-9. PubMed ID: 26811457
[TBL] [Abstract][Full Text] [Related]
16. Novel treatment concepts in Hodgkin lymphoma.
Glimelius I; Diepstra A
J Intern Med; 2017 Mar; 281(3):247-260. PubMed ID: 27991731
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
18. [Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma].
Michot JM; Lazarovici J
Rev Prat; 2023 Jun; 73(6):641-650. PubMed ID: 37458554
[TBL] [Abstract][Full Text] [Related]
19. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.
Moskowitz AJ
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):207-212. PubMed ID: 30504312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
